Avenue Therapeutics, Inc.

ATXI Healthcare Biotechnology

Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million. In the quarter to June 2026, EPS fell 290.9% and free cash flow fell 169.9%, each against the same quarter a year earlier.

0.43 0.00 0.00%
Market cap
$680.0K
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
n/a
Altman Z
−51.47
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.40 1.94 2.67 2.62
Net Debt/EBITDA
2.75 3.39 3.80 5.12
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.13) (0.27) 0.12
Book value per Share
0.17 0.36 0.59 0.72
Free Cash Flow
(0.47) (0.44) (0.85) 0.38
Other line items

Show all line items

Columns are period end dates